Biosig Technologies Inc

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioSig Technologies Inc (NASDAQ: BSGM) has priced its previously announced underwritten public offering of 2.5 million shares at $4.00 per share, representing a discount of 8% from the last close price of $4.35 on Thursday. The gross proceeds will be approximately $10 million, or roughly $11.5 million, if the underwriter exercises its option to purchase an additional 15% of the number of shares.

BioSig Technologies Raises $10M Via Equity Issued At $4/Share

BioSig Technologies Inc (NASDAQ:BSGM) has announced the pricing of its underwritten public offering to raise about $10 million.  In a statement, the company said it could gain roughly an additional $1.5 million in gross proceeds if the underwriter buys an additional 15% in shares.

BioSig announces pricing of its $10M offering of common stock

According to recent reports, the global electroceuticals/bioelectric medicine market is currently worth $16.8 billion and is projected to reach $21.5 billion by 2026, at a compound annual growth rate (CAGR) of 5.0% BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company, unlocks the future of bioelectronic medicine with its PURE EP System™. The company recently increased its procedural volume targets to 15,000 due to accelerated technology usage, after delivering 425 procedures at the end of 2020.

BioSig Completes 1,000 Patient Cases and Expects 1,500 more at the end of 2021

BioSig Technologies Inc (NASDAQ:BSGM) has announced that physicians have completed 1,000 patient cases with its technology across nine installation sites. The company's non-invasive computerized technology, the PURE EP system, aims to drive procedural efficiency and efficacy in electrophysiology.

BioSig says physicians have completed 1,000 patient cases with its PURE EP system technology across nine US installation sites

The Company recently increased its procedural volume targets due to accelerated technology usage BioSig expands its commercial team to target technology adoption across three strategic regions

BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology.

Westport, CT, June 30, 2021 (GLOBE NEWSWIRE) -- ﻿BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that physicians have completed 1000 patient cases with its technology across nine installation sites.

BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology

Presentation to highlight clinical applications of the Company's latest software for arrhythmia care Presentation to highlight clinical applications of the Company's latest software for arrhythmia care

BioSig's Signal Processing Technology for Electrophysiology To Be Featured During 2021 Stanford Biodesign New Arrhythmia Technologies Retreat

Abstracts are due to be presented by physician users and research investigators from two leading institutions Abstracts are due to be presented by physician users and research investigators from two leading institutions

BioSig's Signal Processing System for Electrophysiology Featured in Two Clinical and Scientific Presentations during the annual Heart Rhythm 2021 convention

BioSig Technologies Inc (NASDAQ:BSGM) has announced that it will present an exhibit at the Heart Rhythm 2021 convention, held July 28-31 at the Boston Convention and Exhibition Center. The company's executive leadership, and clinical, commercial and engineering teams will host a series of presentations at booth 849 that will showcase the latest clinical data and demonstrate the newest software features of its PURE EP System, the non-invasive Class 2 device that aims to drive procedural efficiency and efficacy in electrophysiology.

BioSig Technologies to present data from a study of its PURE EP system at Heart Rhythm 2021 in July

Presentation on Tuesday, June 8, 2021, at 5 PM ET Presentation on Tuesday, June 8, 2021, at 5 PM ET

BioSig Technologies, Inc. to Present at the LD Micro Invitational XI Virtual Event

Westport, CT, May 28, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Natasha Drapeau, Executive Vice President of BioSig Technologies, Inc. would be presenting at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021, at 2 pm ET.

BioSig Technologies, Inc. to Present at the Jefferies Virtual Healthcare Conference

Westport, CT, May 21, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Ken Londoner, Chairman, and CEO of BioSig Technologies, Inc. will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. The presentation will be available from 8am EST – 5pm EST  on the conference website Oppenheimer MedTech, Tools, & Diagnostics Summit (wsw.com) . The Company will also be available for one-on-one investor meetings.

BioSig Technologies, Inc. to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit

The Company sees increased technology usage across its installed base and anticipates enrolling to at least 1500 cases by the end of 2021 44 physicians have conducted over 800 arrhythmia patient cases to date

BioSig Sees Increased Case Volume from Expanding Base of Medical Centers Using Its Proprietary Signal Processing System.

BioSig Technologies Inc (NASDAQ:BSGM), which is commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has increased its patient case goal to at least 1,500 procedures by the end of 2021. BioSig's non-invasive computerized technology, the PURE EP System, aims to drive procedural efficiency and efficacy in electrophysiology.

BioSig Technologies increases patient case goal to 1,500 procedures by end of 2021

Westport, CT, May 04, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it increased the patient case goal from 1000 to at least 1500 procedures by the end of 2021.

BioSig Sees Increased Case Volume from Expanding Base of Medical Centers Using Its Proprietary Signal Processing System

BioSig Technologies, Inc. (NASDAQ:BSGM) has announced that physicians at Mayo Clinic's campus in Phoenix, Arizona have started using the company's PURE EP System in patient cases treating cardiac arrhythmias. The 30-day clinical evaluation of the PURE EP System is being conducted by the cardiac electrophysiologists Win-Kuang Shen, Hichan El Masry, Arturo Valverde, and Luis Scott.

BioSig says physicians at Mayo Clinic's campus in Phoenix, Arizona have started using its PURE EP System in patient cases treating cardiac arrhythmias

Westport, CT, April 27, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the physicians at Mayo Clinic's campus in Phoenix, Arizona have started using the Company's PURE EP(tm) System in the patient cases treating cardiac arrhythmias.

BioSig's PURE EP(tm) System Evaluated with Patients at Mayo Clinic in Arizona

MedTech company BioSig Technologies, Inc.'s (NASDAQ: BSGM) first commercial product — the PURE EP system — is gaining traction with physicians and patients. What Happened: BioSig's PURE EP system, which is intended to treat cardiac arrhythmias, is now being used by physicians at the Mayo Clinic's campus in Phoenix, Arizona, the company said in a release Tuesday.

BioSig's Cardiac Signal Processing System Now Used At Mayo Clinic's Phoenix Campus

BioSig Technologies Inc (NASDAQ:BSGM), which is commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has added two experienced electrophysiology regional directors to lead its commercial expansion across the southeast and central regions of the US. The company said Robert Sandler, who will lead regional sales across Texas, brings more than 25 years of sales experience in medical devices.

BioSig taps two regional directors to lead its commercial expansion across southeast and central regions of the US

Two seasoned MedTech sales executives join the Company to lead regional rollouts of the PURE EP System (TM), an electrophysiology system for arrhythmia procedures Two seasoned MedTech sales executives join the Company to lead regional rollouts of the PURE EP System (TM), an electrophysiology system for arrhythmia procedures

BioSig Expands Commercial Team in Two Strategic Regions

BioSig Technologies, Inc. (NASDAQ:BSGM) has announced the release of the PURE EP Software Version 4. The latest release builds on the main system capabilities of the PURE EP while improving the overall user experience.

BioSig Technologies announces release of the PURE EP Software Version 4

Westport, CT, April 14, 2021 (GLOBE NEWSWIRE) -- The latest release represents the most advanced software version of the PURE EPTM System, signal processing technology for treatments of irregular heartbeats

BioSig Launches Enhanced Signal Processing Capabilities for Advanced Cardiac Signal Analysis Through its Electrophysiology Platform

BioSig Technologies Inc (NASDAQ:BSGM) said it has completed enrollment in the PURE EP 2.0 clinical trial. The multi-center, prospective clinical trial was conducted at the Texas Cardiac Arrhythmia Institute at St.

BioSig Technologies completes enrollment in PURE EP 2.0 clinical trial

Westport, CT, April 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced it completed enrollment in the PURE EP 2.0 clinical trial.

BioSig Completes Enrollment in the PURE EP 2.0 Clinical Study

Westport, CT, April 09, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it had been invited by, and accepted, an invitation to join the Alliance for Artificial Intelligence in Healthcare (AAIH), following BioSig's major patent awards for its AI-based platform that the Company recently won from the U.S. Patent Office.

News for Biosig Technologies Inc Stock (BSGM)